Progenics Pharmaceuticals, Inc.
http://www.progenics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Progenics Pharmaceuticals, Inc.
Protein Degradation Leader Nurix Prepares First Clinical Trial
After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.
Intra-Cellular's Lumateperone Poised For New Bipolar Depression Opportunity
The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.
Finance Watch: 2020 Is Four Biopharma IPOs Away From Matching 2019
With 46 initial public offerings in the US by drug developers so far – including recent launches by Kymera, Inhibrx and Harmony – 2020 will easily beat last year’s 50 IPOs. In follow-on offerings and VC deals, newly public Schrodinger raised $346.5m and Tango’s $50m equity financing.
Sanofi Impacted By COVID 19 Headwinds, But Dupixent Powers Forward
Company keeps on track on for 2020 earnings target despite pandemic's hit to general medicines and vaccines sales.
Company Information
- Industry
- Biotechnology
- Digital Health
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
- Other Names / Subsidiaries
-
- Molecular Insight Pharmaceuticals, Inc.
- PSMA Development Company
- UR Labs (URL)